Randomized trial of lifestyle modification and pharmacotherapy for obesity

New England Journal of Medicine

Volumn 353, Issue 20, 2005, Pages 2111-2120

  Wadden, Thomas A ^a   Berkowitz, Robert I ^a,b   Womble, Leslie G ^a   Sarwer, David B ^a   Phelan, Suzanne ^c   Cato, Robert K ^a   Hesson, Louise A ^a   Osei, Suzette Y ^a,d   Kaplan, Rosalind ^e   Stunkard, Albert J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c BROWN UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; SIBUTRAMINE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BREAST CANCER; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; EXERCISE; FEMALE; FOOD INTAKE; HEART PALPITATION; HEPATITIS C; HUMAN; INJURY; LIFESTYLE; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYNEUROPATHY; PREGNANCY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; WEIGHT REDUCTION;

ADULT; APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; COUNSELING; CYCLOBUTANES; EXERCISE; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; PSYCHOTHERAPY, GROUP; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; WEIGHT LOSS;

EID: 27844487932     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa050156     Document Type: Article

References (33)

1. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002;346:591-602.
2. Meridia (sibutramine hydrochloride monohydrate). N. Chicago, Ill.: Abbott Laboratories, 2004 (package insert).
3. Xenical (orlistat). Nutley, N.J.: Roche Pharmaceuticals, 1999 (package insert).
4. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356:2119-25.
5. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-72.
6. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the Evidence Report. Obes Res 1998;6:Suppl 2:51S-209S. [Erratum, Obes Res 1998;6:464.]
7. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000;84:441-61.
8. Wing RR. Behavioral weight control. In: Wadden TA, Stunkard AJ, eds. Handbook of obesity treatment. New York: Guilford Press, 2002:301-16.
9. Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004;27:2067-73.
10. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4:263-70.
11. Phelan S, Wadden TA. Combining behavioral and pharmacological treatments for obesity. Obes Res 2002;10:560-74.
12. Barkeling B, Elfhag K, Rooth P, Rossner S. Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome. Int J Obes Relat Metab Disord 2003;27:693-700.
13. Craighead LW, Stunkard AJ, O'Brien RM. Behavior therapy and pharmacotherapy for obesity. Arch Gen Psychiatry 1981;38:763-8.
14. Craighead LW. Sequencing of behavior therapy and pharmacotherapy for obesity. J Consult Clin Psychol 1984;52:190-9.
15. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8. [Erratum, N Engl J Med 1997;337:1783.]
16. Wadden TA, Berkowitz RI, Vogt RA, Steen SN, Stunkard AJ, Foster GD. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. Obes Res 1997;5:218-26.
17. Serdula MK, Khan LK, Dietz WH. Weight loss counseling revisited. JAMA 2003;289:1747-50.
18. Haffner SM, Kennedy E, Gonzalez C, Stein MP, Miettinen H. A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care 1996;19:1138-41.
19. Shape Up America. On your way to fitness. Wilton: Connecticut Marketing Associates, 1996.
20. Brownell KD, ed. The LEARN program for weight control. 7th ed. Dallas: American Health Publishing, 1998.
21. Brownell KD, Rodin J. The weight maintenance survival guide. Dallas: Brownell & Hager, 1990.
22. Brownell KD, Wadden TA. The LEARN program for weight control: special medication edition. Dallas: American Health Publishing, 1999.
23. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003;289:1805-12.
24. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001;161:218-27.
25. SPSS for Windows, version 11.0. Chicago: SPSS, 2000.
26. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
27. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004;8:1-182.
28. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003.
29. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003;11:1116-23.
30. Wee CC, Hamel MB, Davis RB, Phillips RS. Assessing the value of weight loss among primary care patients. J Gen Intern Med 2004;19:1206-11.
31. Hollon SD, DeRubeis RJ. Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychol Bull 1981;90:467-77.
32. Brightwell DR, Naylor CS. Effects of a combined behavioral and pharmacologic program on weight loss. Int J Obes 1979;3:141-8.
33. McTigue KM, Harris R, Hemphill B, et al. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Service Task Force. Ann Intern Med 2003;139:933-49.